By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – South Korean life sciences company Chemizon, a division of Optomagic, said today that it will support Shenogen Pharma Group's drug development programs aimed at developing small molecule therapeutics for cancer and endocrine disorders.

Chemizon will be responsible for a range of services and activities, including lead optimization, assay development, computational chemistry, animal pharmacology, and absorption, distribution, metabolism, and excretion processes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.